These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 29035749)
1. Chemical remodeling cell surface glycans for immunotargeting of tumor cells. Li X; Xu X; Rao X; Tian Y; Yi W Carbohydr Res; 2017 Nov; 452():25-34. PubMed ID: 29035749 [TBL] [Abstract][Full Text] [Related]
2. Targeting Tumor Cells by Natural Anti-Carbohydrate Antibodies Using Rhamnose-Functionalized Liposomes. Li X; Rao X; Cai L; Liu X; Wang H; Wu W; Zhu C; Chen M; Wang PG; Yi W ACS Chem Biol; 2016 May; 11(5):1205-9. PubMed ID: 26982552 [TBL] [Abstract][Full Text] [Related]
3. Rhamnose glycoconjugates for the recruitment of endogenous anti-carbohydrate antibodies to tumor cells. Sheridan RT; Hudon J; Hank JA; Sondel PM; Kiessling LL Chembiochem; 2014 Jul; 15(10):1393-8. PubMed ID: 24909955 [TBL] [Abstract][Full Text] [Related]
4. Synthesis of a single-molecule L-rhamnose-containing three-component vaccine and evaluation of antigenicity in the presence of anti-L-rhamnose antibodies. Sarkar S; Lombardo SA; Herner DN; Talan RS; Wall KA; Sucheck SJ J Am Chem Soc; 2010 Dec; 132(48):17236-46. PubMed ID: 21080675 [TBL] [Abstract][Full Text] [Related]
5. Practical Antibody Recruiting by Metabolic Labeling with Caged Glycans. Milawati H; Manabe Y; Matsumoto T; Tsutsui M; Ueda Y; Miura A; Kabayama K; Fukase K Angew Chem Int Ed Engl; 2023 Jun; 62(25):e202303750. PubMed ID: 37042088 [TBL] [Abstract][Full Text] [Related]
6. Biomarker-Based Metabolic Labeling for Redirected and Enhanced Immune Response. Li S; Yu B; Wang J; Zheng Y; Zhang H; Walker MJ; Yuan Z; Zhu H; Zhang J; Wang PG; Wang B ACS Chem Biol; 2018 Jun; 13(6):1686-1694. PubMed ID: 29792670 [TBL] [Abstract][Full Text] [Related]
7. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. Green SK; Karlsson MC; Ravetch JV; Kerbel RS Cancer Res; 2002 Dec; 62(23):6891-900. PubMed ID: 12460904 [TBL] [Abstract][Full Text] [Related]
8. L-rhamnose antigen: a promising alternative to α-gal for cancer immunotherapies. Chen W; Gu L; Zhang W; Motari E; Cai L; Styslinger TJ; Wang PG ACS Chem Biol; 2011 Feb; 6(2):185-91. PubMed ID: 21043478 [TBL] [Abstract][Full Text] [Related]
9. Antibody recognition of aberrant glycosylation on the surface of cancer cells. Soliman C; Yuriev E; Ramsland PA Curr Opin Struct Biol; 2017 Jun; 44():1-8. PubMed ID: 27821276 [TBL] [Abstract][Full Text] [Related]
10. O-methylated glycans from Toxocara are specific targets for antibody binding in human and animal infections. Schabussova I; Amer H; van Die I; Kosma P; Maizels RM Int J Parasitol; 2007 Jan; 37(1):97-109. PubMed ID: 17087964 [TBL] [Abstract][Full Text] [Related]
11. Synthetic Rhamnose Glycopolymer Cell-Surface Receptor for Endogenous Antibody Recruitment. De Coen R; Nuhn L; Perera C; Arista-Romero M; Risseeuw MDP; Freyn A; Nachbagauer R; Albertazzi L; Van Calenbergh S; Spiegel DA; Peterson BR; De Geest BG Biomacromolecules; 2020 Feb; 21(2):793-802. PubMed ID: 31829561 [TBL] [Abstract][Full Text] [Related]
12. Extracellular 37-kDa antigenic protein from Actinobacillus actinomycetemcomitans induces TNF-alpha, IL-1 beta, and IL-6 in murine macrophages. Tani Y; Tani M; Kato I J Dent Res; 1997 Sep; 76(9):1538-47. PubMed ID: 9294487 [TBL] [Abstract][Full Text] [Related]
13. Cell membrane-camouflaged liposomes for tumor cell-selective glycans engineering and imaging in vivo. Liu Z; Wang F; Liu X; Sang Y; Zhang L; Ren J; Qu X Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301864 [TBL] [Abstract][Full Text] [Related]
14. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Pedersen MW; Jacobsen HJ; Koefoed K; Hey A; Pyke C; Haurum JS; Kragh M Cancer Res; 2010 Jan; 70(2):588-97. PubMed ID: 20068188 [TBL] [Abstract][Full Text] [Related]
15. Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain. Park H; Kim D; Kim E; Sa JK; Lee HW; Yu S; Oh J; Kim SH; Yoon Y; Nam DH Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28902178 [TBL] [Abstract][Full Text] [Related]
16. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity. Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181 [TBL] [Abstract][Full Text] [Related]
17. Differential N-glycosylation of a monoclonal antibody expressed in tobacco leaves with and without endoplasmic reticulum retention signal apparently induces similar in vivo stability in mice. Triguero A; Cabrera G; Rodríguez M; Soto J; Zamora Y; Pérez M; Wormald MR; Cremata JA Plant Biotechnol J; 2011 Dec; 9(9):1120-30. PubMed ID: 21819534 [TBL] [Abstract][Full Text] [Related]
18. Targeting to tumor necrotic regions with biotinylated antibody and streptavidin modified liposomes. Pan H; Han L; Chen W; Yao M; Lu W J Control Release; 2008 Feb; 125(3):228-35. PubMed ID: 18022270 [TBL] [Abstract][Full Text] [Related]
19. Tk, a new colon tumor-associated antigen resulting from altered O-glycosylation. Meichenin M; Rocher J; Galanina O; Bovin N; Nifantev N; Sherman A; Cassagnau E; Heymann MF; Bara J; Fraser RH; Le Pendu J Cancer Res; 2000 Oct; 60(19):5499-507. PubMed ID: 11034094 [TBL] [Abstract][Full Text] [Related]
20. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo. Shi C; Cao H; He W; Gao F; Liu Y; Yin L Biomed Pharmacother; 2015 Jul; 73():48-57. PubMed ID: 26211582 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]